Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $24.58 USD
Change Today -0.095 / -0.39%
Volume 444.0
As of 9:30 AM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

takeda pharmaceutic-sp adr (TKPYY) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/6/15 - $27.52
52 Week Low
12/16/14 - $20.36
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

takeda pharmaceutic-sp adr (TKPYY) Details

Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, marketing, sale, and import/export of pharmaceutical drugs worldwide. It provides products in various therapeutic areas, including cardiovascular and metabolic, respiratory and immunology, oncology, central nervous system, general medicine, vaccines, and consumer healthcare drugs and quasi-drugs. The company has strategic partnership with BioMotiv, LLC; and a collaboration agreement with Mersana Therapeutics Inc. and Queen Mary University of London. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Osaka, Japan.

31,328 Employees
Last Reported Date: 06/26/15
Founded in 1781

takeda pharmaceutic-sp adr (TKPYY) Top Compensated Officers

Chief Executive Officer, President and Repres...
Total Annual Compensation: ¥230.0M
Senior Managing Director, Corporate Strategy ...
Total Annual Compensation: ¥85.0M
Compensation as of Fiscal Year 2015.

takeda pharmaceutic-sp adr (TKPYY) Key Developments

Drugs for Neglected Diseases Initiative and Takeda Pharmaceutical Company Limited Collaborate for Lead Optimization for Aminopyrazole Series for Visceral Leishmaniasis

Drugs for Neglected Diseases initiative and Takeda Pharmaceutical Company Limited announced that they have signed an agreement to collaborate in the 'Lead Optimization Program' aimed at identifying the best compound among aminopyrazole series for developing an innovative drug for the treatment of visceral leishmaniasis (VL). The program is being funded by Global Health Innovative Technology Fund (GHIT). GHIT Fund is investing approximately ¥400 million into DNDi for the program. DNDi and Takeda are working on the lead optimization of the aminopyrazole series. In preclinical trials, the aminopyrazole series exhibited good antiparasitic activity, and are expected to be highly safe and effective. DNDi and Takeda consider that short-course oral administration of the drug is effective for the treatment, and therefore it is expected to be a novel drug which will be different from the existing therapeutics for VL. In addition to this collaboration agreement, DNDi and Takeda entered into partnership agreements such as the 'drug discovery booster for accelerating and promoting the discovery of new drugs for treating leishmaniasis and Chagas disease'. DNDi and Takeda aim to contribute towards treating 'Neglected Tropical Diseases' through these efforts.

Takeda Pharmaceutical Co. Consolidate its U.S. Vaccine Operations in Boston/Cambridge Area; Closes Facilities in Madison, Fort Collins, Bozeman and Deerfield, Illinois

Takeda Pharmaceutical Co. announced that it is consolidating its U.S. vaccine operations in the Boston/Cambridge area. The company closing facilities in Madison; Fort Collins, Colorado; Bozeman, Montana; and Deerfield, Illinois.

Takeda Pharmaceutical Company Limited Submits New Drug Application for ixazomib for Patients with Relapsed/Refractory Multiple Myeloma

Takeda Pharmaceutical Company Limited announced that a new drug application (NDA) has been submitted to the United States (U.S.) Food and Drug Administration (FDA) for ixazomib, an investigational oral proteasome inhibitor for the treatment of patients with relapsed and/or refractory multiple myeloma. The NDA submission was based on the pivotal Phase 3 trial TOURMALINE-MM1, an international, randomized, double-blind, placebo controlled clinical trial of 722 patients designed to evaluate the superiority of ixazomib plus lenalidomide and dexamethasone over placebo plus lenalidomide and dexamethasone in adult patients with relapsed and/or refractory multiple myeloma. Patients continue to be treated in this trial and evaluated for long-term outcomes.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TKPYY:US $24.58 USD -0.095

TKPYY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $51.10 USD +0.16
Baxter International Inc $38.47 USD +0.38
Becton Dickinson and Co $150.69 USD +0.81
Biogen Inc $316.41 USD -3.52
Merck KGaA €94.72 EUR +2.20
View Industry Companies

Industry Analysis


Industry Average

Valuation TKPYY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.6x
Price/Book 2.2x
Price/Cash Flow 152.6x
TEV/Sales 1.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TAKEDA PHARMACEUTIC-SP ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at